N/A N=16 Early Diagnosis of Diastolic Dysfunction and Reliability of DSE in Detecting Stress Diastolic Dysfunction
Diastolic Dysfunction
Primary: Change in Left Ventricle Mean Diastolic Pressure — 3.3 mmHg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=229 The Effects of Systolic Blood Pressure Lowering on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction
Hypertension · Diastolic Dysfunction
Primary: Change in Lateral Mitral Annular Myocardial Relaxation Velocity — 1.544; 1.476 cm/s
Phase 3 N=216 Evaluating the Effectiveness of Sildenafil at Improving Health Outcomes and Exercise Ability in People With Diastolic Heart Failure (The RELAX Study)
Heart Failure
Primary: Exercise Capacity, as Determined by Peak Oxygen Uptake — -0.07; -0.12 ml/min/kg
Phase 4 N=130 Myocardial Dysfunction in Type 2 Diabetes Mellitus (T2DM)
Type 2 Diabetes · Coronary Heart Disease
Primary: Change in E to A Ratio — 1.04; 1.25 Ratio — p=<0.01
N/A N=53 Effects of Nebivolol on Exercise Tolerance and Left Ventricular Systolic and Diastolic Function
Hypertension
Primary: Resting Systolic BP — 135 mm Hg — p=<0.05
N/A N=28 Rhode Island Diastolic Dysfunction - Heart Failure
Heart Failure · Cardiovascular Disease
Primary: Change From Baseline in Oxygen Consumption During Maximal Bike Exercise — 14.45; 14.18 mL/kg/min — p=0.823
Phase 2 N=192 A Study of the Effectiveness of Sitaxsentan Sodium in Patients With Diastolic Heart Failure
Diastolic Heart Failure
Primary: Change From Baseline in Treadmill Exercise Time at Maintenance Phase Week 24 — 424.5; 485.0; 89.5; 37.0 Seconds — p=0.0302
N/A N=14 Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure
Diastolic Heart Failure · Hypertensive Heart Disease
Primary: Brachial Artery Flow-mediated Dilation (FMD) — 5; 8 % dilation — p=.17
N/A N=80 Improving Metabolic Health in Patients With Diastolic Dysfunction
Obesity · Heart Failure, Diastolic · Metabolic Syndrome
Primary: Change From Baseline at 1 Year in Myocardial Lipid Content — -0.16; -0.18; -0.53; -0.19 %fat/water
N/A N=24 Noninvasive Neuromodulation to Reserve Diastolic Dysfunction
Heart Failure, Diastolic
Primary: Echocardiographic Markers of Diastolic Dysfunction — -21.2; -23.0 percent
Phase 2 N=50 Radiofrequency-based Speckle Tracking Echocardiography to Evaluate Diastolic Function
Heart Failure, Diastolic
Primary: Diastolic Circumferential Strain Rate During Isovolumic Relaxation — 0.61; 0.37; 0.34 1/sec
N/A N=19 High Intensity Interval Exercise in Diastolic Heart Failure
Diastolic Heart Failure
Primary: Left Ventricular Diastolic Dysfunction — 2.1; 2; 1.3; 2.2 DD grade
N/A N=30 Effect of Intradialytic Exercise on Left Ventricular Diastolic Function in Hemodialysis Patients
Renal Dialysis · Hemodiafiltration · Diastolic Dysfunction
Primary: Left Ventricular Diastolic Function Category — 15; 15; 5; 5 Participants — p=0.06
N/A N=100 Exercise Intolerance in Elderly Patients With Diastolic Heart Failure
Heart Failure, Diastolic · Obesity
Primary: Exercise Capacity — 15.5; 15.5; 14.1; 16.6 ml/kg/min — p=<0.001
Phase 2 N=22 Study to Determine How Cialis Effects the Renal Function in Response to Volume Expansion in Preclinical Diastolic Cardiomyopathy (Aim3)
Cardiomyopathy · Renal Impairment
Primary: Change in Urinary Sodium Excretion — 74.43; 29.11 MEq/min — p=0.04
N/A N=111 Left Atrial Distensibility to Predict Left Ventricular Filling Pressure and Prognosis in Patients With Severe Mitral Regurgitation
Mitral Valve Insufficiency · Atrial Fibrillation · Heart Failure
Primary: Left Ventricular Filling Pressure More Than 15 mmHg Measured by Left Ventricular Catheterization — 25.5 mmHg
Phase 4 N=90 Diuretics and Dopamine in Heart Failure With Preserved Ejection Fraction
Heart Failure, Diastolic
Primary: Percent Change in Serum Creatinine at 72 Hours. — 4; 11; 5; 20 percent change in serum creatinine
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
Phase 2 N=44 Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
Heart Failure · Congestive Heart Failure
Primary: Wave Reflection Magnitude — 0.38; 0.44; 0.37 dimensionless ratio
Phase 3 N=47 Effects of Ranolazine on Coronary Flow Reserve in Symptomatic Diabetic Patients and CAD
Diabetes, Type I · Diabetes, Type II · Angina
Primary: Change in Post-exercise Coronary Vasodilator Reserve — -4; 2 % change
N/A N=101 Heart Function in Patients Assessed for Sleep Apnoea
Heart Failure With Preserved Ejection Fraction · Sleep Disordered Breathing · Heart Failure With Normal Ejection Fraction
Primary: Number of Participants With Unrecognised Heart Failure With Preserved Ejection Fraction (HFpEF) in Cohort With Clinically Suspected Sleep Disordered Breathing (SDB) — 7…
Phase 4 N=10 Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
Pulmonary Hypertension · Diastolic Left Ventricular Dysfunction
Primary: Percent Change in mPAP, PAOP and Pulmonary Vascular Resistance (PVR) — -21; -39; -4.0 percentage change
Phase 2 N=153 CoQ10 and D-ribose in Patients With Diastolic Heart Failure
Heart Failure, Diastolic
Primary: Change in Health Status of Patients With HFpEF — 4.15; 26.56; 29.97; 33 Scores on a scale
N/A N=51 Effect of Weight Loss on Myocardial Metabolism and Cardiac Relaxation in Obese Adults
Obesity
Primary: Total Myocardial Oxygen Consumption (MVO2) — 1064; 1202; 947; 835 µmol/min
Phase 2 N=58 Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Congestive Heart Failure
Primary: Change in Natriuresis (Urinary Sodium Excretion) in Control Subjects at 60 Minutes After Volume Expansion Compared to Baseline in Response to Placebo Treatment — 87.19…
Phase 4 N=76 Cardiovascular Function in COPD Patients
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI) in the 6th Week of Treatment — 2.855; 2.317 Millilitre/ meter^2 (mL/m^2) — p=0.6331
Phase 2 N=16 Investigate the Effect of AZD1305 on Patients With Left Ventricular Dysfunction
Left Ventricle Function
Primary: Left Ventricular Ejection Fraction (LVEF), Change From Baseline — 2.00; -3.25 Percent change
N/A N=123 Pre-clinical Cardiac Dysfunction Among Asymptomatic Hypertensive Patients
Hypertension · High Blood Pressure · Ventricular Hypertrophy
Primary: Clinically Significant Difference in Blood Pressure Lowering, Health Status and Quality of Life — -3.3; -4.9 mm Hg
Phase 2 N=26 Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs
Congestive Heart Failure · Heart Failure, Diastolic
Primary: the Safety Profile of CAP 1002; Any Subjects Experiencing Any Safety Related Events During or Post Intracoronary Delivery and During the Follow up Period. — 0; 1…
N/A N=36 Exercise,Metabolic Syndrome and Weight Regain (Echocardiography Substudy)
Metabolic Syndrome · Obesity
Primary: Mean Resting E/E' — 7.01 ml/min/kg — p==0.14